Antibiotic combination therapy with acid suppression

This page covers all Antibiotic combination therapy with acid suppression drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome, Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis.

Targets

Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome · Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis

Marketed (2)

• PPI-amoxicillin-clarithromycin · National Taiwan University Hospital · Gastroenterology / Infectious Disease
  This is a triple-therapy combination that uses a proton pump inhibitor to reduce stomach acid while amoxicillin and clarithromycin work synergistically as antibiotics to eradicate Helicobacter pylori infection.
• PPI, amoxicillin, metronidazole and clarithromycin · Infante, Javier Molina, M.D. · Gastroenterology / Infectious Disease
  This is a quadruple therapy regimen that eradicates Helicobacter pylori by combining acid suppression with three antibiotics that target bacterial protein synthesis and DNA.

Patent intelligence

• antibiotic combination therapy with acid suppression patent landscape — aggregated cliff calendar, attackable patents, originator estates